Insud Pharma

What Insud Pharma does

Insud Pharma is a privately held Spanish pharmaceutical group headquartered in Madrid, founded in 1977 by Silvia Gold and Hugo Sigman, and currently led by the next generation under Leandro and Lucas Sigman (Lucas Sigman serving as CEO). The group operates end-to-end across the pharmaceutical value chain, offering CDMO/CMO services spanning active pharmaceutical ingredient (API) manufacturing, finished dosage form (FDF) production, and commercialization of branded medicines for human and animal health. It runs approximately 21 manufacturing plants and 15 R&D centers across Spain, Italy, Argentina, India and Turkey, with a 2,000+ person commercial network reaching customers in 40+ countries and an aggregate presence spanning 50+ countries.

The group is organized around five core business units: Chemo (a global leader in API and FDF manufacturing with 100+ APIs and 200+ product presentations); Exeltis (branded medicines with strategic focus on women's health and CNS); mAbxience (biopharmaceuticals and biosimilars, with single-use bioreactor facilities in Spain, Turkey and Argentina totaling up to 16,000L capacity); Algenex (recombinant protein production using CRISBIO technology); and Bionanopharma (nanofiber and nanoparticle drug delivery via electrospraying microencapsulation). Specialty platforms include steroid manufacturing at 150,000+ L scale, vaginal ring technology (10 MM/year), proton pump inhibitor production (leader in European omeprazole and lansoprazole), oligonucleotide development, and inhalation/formulation capabilities supported by three of the world's largest fluid beds at 1,300 kg/batch.

Insud Pharma generates revenue through multiple streams: contract manufacturing and development fees from third-party pharmaceutical clients (CDMO/CMO services via Chemo and mAbxience), API sales, sales of branded medicines in human and animal health through Exeltis and other units, and biopharmaceutical commercialization including biosimilars and monoclonal antibodies. Recent strategic activity includes the March 2024 acquisition of the Viatris oral and injectable contraceptives portfolio and the August 2024 acquisition of Agile Therapeutics (~$45M) via Exeltis USA, both targeting women's health expansion. The group is family-controlled with no external institutional investor involvement and is not listed on any public exchange.

Name

Insud Pharma

Legal name

Insud Pharma S.L.

Website

https://insudpharma.com

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Insud Pharma is a privately held, family-controlled Spanish pharmaceutical group offering end-to-end CDMO/CMO services and branded medicines across APIs, finished dosage forms, biopharmaceuticals, and women's health, operating 21 plants and a 2,000-person commercial network in 50+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• CDMO pharmaceutical services
• API manufacturing
• Branded pharmaceutical products
• Biopharmaceutical contract manufacturing
• Finished dosage forms

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices15 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. CDMO/CMO Manufacturing Services: Contract manufacturing and development services for pharmaceutical companies, offering API production and finished dosage form manufacturing through Chemo, Exeltis, and mAbxience units.
2. API Production and Sales: Chemo is a world leader in R&D and manufacturing of over 100 active pharmaceutical ingredients and more than 50 medicines with over 200 product presentations.
3. Branded Pharmaceutical Products: Sale and commercialization of branded medicines for human and animal health through Exeltis and other business units. Focus on women's health, CNS, and various therapeutic areas.
4. Biopharmaceutical Products: mAbxience develops, manufactures and commercializes biopharmaceutical products including monoclonal antibodies and biosimilars.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Insud Pharma is a global pharmaceutical group that delivers end-to-end CDMO and CMO services spanning the full value chain from R&D and active pharmaceutical ingredient (API) manufacturing to finished dosage form (FDF) production and commercialization of branded medicines. It operates through five main business units (Chemo, Exeltis, mAbxience, Algenex and Bionanopharma) and approximately 20 manufacturing plants that produce over 100 APIs, 50+ medicines with 200+ presentations, monoclonal antibodies, biosimilars, recombinant proteins and nanofiber-based drug delivery products for human and animal health.

Product overview

Insud Pharma is a global pharmaceutical group providing CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization) services, operating end-to-end across the entire pharmaceutical value chain from R&D to manufacturing and commercialization of APIs, FDFs (Finished Dosage Forms), and branded medicines for human and animal health. The company's portfolio consists of five main business units: Chemo (API and FDF manufacturing), Exeltis (branded medicines focused on Women's Health and CNS), mAbxience (biopharmaceuticals and biosimilars), Algenex (recombinant proteins), and Bionanopharma (nanofiber drug delivery). Insud Pharma operates through approximately 20 manufacturing plants across Europe, Americas, and Asia, and 15+ R&D centers, offering CMO/CDMO services to third-party clients alongside its own product portfolio. The group was founded in 1977 and maintains headquarters in Madrid, Spain.

Differentiator

Problem solved

Functional benefit

Brands

• Chemo: A global leader in R&D and manufacturing of over 100 active pharmaceutical ingredients (APIs) and more than 50 medicines with over 200 product presentations.
• Exeltis
• mAbxience
• Algenex
• Bionanopharma
• Mundo Sano
• Insud Power
• ChemoStart

Products and services

• Chemo APIs and Finished Dosage Forms

Quantifiable outcome

• Leader in European omeprazole and lansoprazole market
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and strategic.

• Agile TherapeuticscoreStrategic or Co-development Partner · 26 August 2024Acquisition completed through merger; Agile Therapeutics became an indirect subsidiary of Insud Pharma via Exeltis USA, Inc. Deal valued at approximately $45 million with $1.52 per share cash payment. Agile develops contraceptive products.
• ViatriscoreStrategic or Co-development Partner · 1 March 2024In March 2024, Insud Pharma acquired the oral and injectable contraceptives portfolio from US-based Viatris, expanding Insud Pharma's women's health offerings and strengthening its position in reproductive healthcare.
• ALGENEX, BIOGÉNESIS BAGÓ, PROALT, CISA-INIA, CSIC, CIC bioGUNEstrategicStrategic or Co-development PartnerCollaboration on DIVAVACEHD project - developing a DIVA vaccine against Epizootic Hemorrhagic Disease (EHD) in cattle using CRISBIO® technology. Combines biotech, AI protein design, preclinical/clinical research, and industrial development.
• Mundo Sano FoundationcoreOthersFamily foundation founded in 1993 by Dr. Roberto Gold, dedicated to improving lives of people affected by neglected diseases (Chagas, dengue, leishmaniosis, geoparasitosis, hydatidosis). Funded by Insud Pharma Group with 5 offices in Latin America and programs in Africa.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Aenova Group: European-headquartered CDMO offering solid dosage forms, semi-solids and sterile injectables, closely overlapping with Insud's Liconsa, León Farma and Universal Farma service lines.
• Recipharm: Privately held CDMO with integrated API, FDF and sterile fill-finish services across Europe, comparable to Chemo's integrated CDMO and Insud's León Farma/Universal Farma injectable operations.
• Siegfried Holding: Public Swiss CDMO focused on API and FDF manufacturing, directly comparable to Chemo's small-molecule and oral solid dose offering.

Emerging players

• Organon: Women's-health-focused pharmaceutical company spun out of Merck, directly comparable to the post-Viatris/Agile Exeltis franchise in contraception, fertility and menopause.
• Theramex: Private global women's-health specialty pharma covering contraception, fertility and menopause; closest pure-play specialist competitor to Exeltis.
• Biocon: Indian biopharmaceutical company with global biosimilars and CDMO exposure, comparable to mAbxience in biosimilar development and to Chemo India Formulation in injectable and oral solid dose manufacturing.

Broad incumbents

• Catalent (Novo Holdings): Large US-headquartered CDMO with strong softgel, oral and biologics fill-finish capabilities; competes with Insud across fill-finish and biosimilar-related services globally.
• Lonza Group: Global CDMO leader with large-scale mammalian and microbial biologics capacity and integrated small-molecule services; sets the competitive benchmark for Insud's mAbxience and Chemo units.
• Samsung Biologics: Korean biologics CDMO operating very large mammalian cell-culture capacity; relevant competitor to mAbxience for biosimilar and mAb manufacturing contracts.

Regional players

• Polpharma: Central European integrated pharma group spanning APIs, FDFs and branded generics with strong regional manufacturing footprint; comparable to Insud on integrated CDMO + branded pharma model in European markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/insudpharma
• LinkedInlinkedin.com/company/insud-pharma
• Instagraminstagram.com/insudpharma/?hl=es

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries22 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insud Pharma